Peringatan Keamanan

IVN-RAT LD50 1300 mg/kg; IPR-MUS LD50 5.2 mg/kg. Marqibo® must only be administered IV because it is fatal if administered by other routes. Marqibo® also has different dosing than vincristine sulphate injection, so attention is needed to prevent overdoses. The most clinically significant adverse effect of vincristine is neurotoxicity.

Vincristine

DB00541

small molecule approved investigational

Deskripsi

Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).

Struktur Molekul 2D

Berat 824.972
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) When intravenously injected into cancer patients, a triphasic serum decay patten was observed. The initial, middle, and terminal half-lives are 5 minutes, 2.3 hours, 85 hours respectively. The range of the terminal half-life is humans is 19 - 155 hours.
Volume Distribusi Within 15 to 30 minutes after injection, over 90% of the drug is distributed from the blood into tissue, where it remains tightly, but not irreversibly, bound.
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Hepatic. Cytochrome P450 isoenzymes of the CYP3A subfamily facilitate the metabolism of vincristine.

Rute Eliminasi

The liver is the major excretory organ in humans and animals. 80% of an injected dose of vincristine sulfate is excreted via feces. 10 - 20% is excreted via urine.

Interaksi Makanan

2 Data
  • 1. Exercise caution with grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum concentration of vincristine.
  • 2. Exercise caution with St. John's Wort. This herb induces CYP3A4 metabolism, which may reduce serum levels of vincristine.

Interaksi Obat

1221 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Vincristine.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vincristine.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Vincristine.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Vincristine.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vincristine.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Vincristine.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Vincristine.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vincristine.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vincristine.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vincristine.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vincristine.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Vincristine.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Vincristine.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Vincristine.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vincristine.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Vincristine.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vincristine.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Vincristine.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Vincristine.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vincristine.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vincristine.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Vincristine.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vincristine.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Vincristine.
Cladribine Vincristine may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Vincristine.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Vincristine.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Vincristine.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Vincristine.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Vincristine.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Vincristine.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Vincristine.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Vincristine.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Vincristine.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Vincristine.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Vincristine.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Vincristine.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Vincristine.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Vincristine.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Vincristine.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Vincristine.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Vincristine.
Fluorouracil The risk or severity of adverse effects can be increased when Vincristine is combined with Fluorouracil.
Propylthiouracil The risk or severity of adverse effects can be increased when Vincristine is combined with Propylthiouracil.
Pentostatin The risk or severity of adverse effects can be increased when Vincristine is combined with Pentostatin.
Methotrexate The risk or severity of adverse effects can be increased when Vincristine is combined with Methotrexate.
Linezolid The risk or severity of adverse effects can be increased when Vincristine is combined with Linezolid.
Clofarabine The risk or severity of adverse effects can be increased when Vincristine is combined with Clofarabine.
Pemetrexed The risk or severity of adverse effects can be increased when Vincristine is combined with Pemetrexed.
Fludrocortisone The risk or severity of adverse effects can be increased when Vincristine is combined with Fludrocortisone.
Sulfasalazine The risk or severity of adverse effects can be increased when Vincristine is combined with Sulfasalazine.
Dacarbazine The risk or severity of adverse effects can be increased when Vincristine is combined with Dacarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Vincristine is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Vincristine is combined with Penicillamine.
Mechlorethamine The risk or severity of adverse effects can be increased when Vincristine is combined with Mechlorethamine.
Azacitidine The risk or severity of adverse effects can be increased when Vincristine is combined with Azacitidine.
Carboplatin The risk or severity of adverse effects can be increased when Vincristine is combined with Carboplatin.
Cytarabine The risk or severity of adverse effects can be increased when Vincristine is combined with Cytarabine.
Azathioprine The risk or severity of adverse effects can be increased when Vincristine is combined with Azathioprine.
Hydroxyurea The risk or severity of adverse effects can be increased when Vincristine is combined with Hydroxyurea.
Mycophenolic acid The risk or severity of adverse effects can be increased when Vincristine is combined with Mycophenolic acid.
Mercaptopurine The risk or severity of adverse effects can be increased when Vincristine is combined with Mercaptopurine.
Thalidomide The risk or severity of peripheral neuropathy can be increased when Thalidomide is combined with Vincristine.
Melphalan The risk or severity of adverse effects can be increased when Vincristine is combined with Melphalan.
Fludarabine The risk or severity of adverse effects can be increased when Vincristine is combined with Fludarabine.
Flucytosine The risk or severity of adverse effects can be increased when Vincristine is combined with Flucytosine.
Capecitabine The risk or severity of adverse effects can be increased when Vincristine is combined with Capecitabine.
Trilostane The risk or severity of adverse effects can be increased when Vincristine is combined with Trilostane.
Procarbazine The risk or severity of adverse effects can be increased when Vincristine is combined with Procarbazine.
Idarubicin The risk or severity of adverse effects can be increased when Vincristine is combined with Idarubicin.
Lomustine The risk or severity of adverse effects can be increased when Vincristine is combined with Lomustine.
Eculizumab The risk or severity of adverse effects can be increased when Vincristine is combined with Eculizumab.
Decitabine The risk or severity of adverse effects can be increased when Vincristine is combined with Decitabine.
Nelarabine The risk or severity of adverse effects can be increased when Vincristine is combined with Nelarabine.
Ciclesonide The risk or severity of adverse effects can be increased when Vincristine is combined with Ciclesonide.
Stepronin The risk or severity of adverse effects can be increased when Vincristine is combined with Stepronin.
Castanospermine The risk or severity of adverse effects can be increased when Vincristine is combined with Castanospermine.
Vorinostat The risk or severity of adverse effects can be increased when Vincristine is combined with Vorinostat.
2-Methoxyethanol The risk or severity of adverse effects can be increased when Vincristine is combined with 2-Methoxyethanol.
Brequinar The risk or severity of adverse effects can be increased when Vincristine is combined with Brequinar.
Thiotepa The risk or severity of adverse effects can be increased when Vincristine is combined with Thiotepa.
Pirfenidone The risk or severity of adverse effects can be increased when Vincristine is combined with Pirfenidone.
Belinostat The risk or severity of adverse effects can be increased when Vincristine is combined with Belinostat.
Trabectedin The risk or severity of adverse effects can be increased when Vincristine is combined with Trabectedin.
Interferon alfa The risk or severity of adverse effects can be increased when Vincristine is combined with Interferon alfa.
Glatiramer The risk or severity of adverse effects can be increased when Vincristine is combined with Glatiramer.
Briakinumab The risk or severity of adverse effects can be increased when Vincristine is combined with Briakinumab.
Human interferon omega-1 The risk or severity of adverse effects can be increased when Vincristine is combined with Human interferon omega-1.
Panobinostat The risk or severity of adverse effects can be increased when Vincristine is combined with Panobinostat.
Mepolizumab The risk or severity of adverse effects can be increased when Vincristine is combined with Mepolizumab.
Abetimus The risk or severity of adverse effects can be increased when Vincristine is combined with Abetimus.
Belatacept The risk or severity of adverse effects can be increased when Vincristine is combined with Belatacept.
Bendamustine The risk or severity of adverse effects can be increased when Vincristine is combined with Bendamustine.
Pralatrexate The risk or severity of adverse effects can be increased when Vincristine is combined with Pralatrexate.
Wortmannin The risk or severity of adverse effects can be increased when Vincristine is combined with Wortmannin.
Eribulin The risk or severity of adverse effects can be increased when Vincristine is combined with Eribulin.
Ruxolitinib The risk or severity of adverse effects can be increased when Vincristine is combined with Ruxolitinib.
Belimumab The risk or severity of adverse effects can be increased when Vincristine is combined with Belimumab.
Teriflunomide The risk or severity of adverse effects can be increased when Vincristine is combined with Teriflunomide.
Dimethyl fumarate The risk or severity of adverse effects can be increased when Vincristine is combined with Dimethyl fumarate.

Target Protein

Tubulin beta chain TUBB
Tubulin alpha-4A chain TUBA4A

Referensi & Sumber

Synthesis reference: Homer L. Pearce, "Method of preparing vincristine." U.S. Patent US4303584, issued November, 1967.
Artikel (PubMed)
  • PMID: 8608515
    Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD: Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer. 1996 Apr 1;77(7):1356-62.
  • PMID: 17355029
    Qweider M, Gilsbach JM, Rohde V: Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report. J Neurosurg Spine. 2007 Mar;6(3):280-3.
  • PMID: 14070392
    JOHNSON IS, ARMSTRONG JG, GORMAN M, BURNETT JP Jr: THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS. Cancer Res. 1963 Sep;23:1390-427.
  • PMID: 10226730
    Gidding CE, Kellie SJ, Kamps WA, de Graaf SS: Vincristine revisited. Crit Rev Oncol Hematol. 1999 Feb;29(3):267-87.

Contoh Produk & Brand

Produk: 12 • International brands: 15
Produk
  • Marqibo
    Kit • 5 mg/5mL • Intravenous • US • Approved
  • Marqibo
    Kit • 5 mg/5mL • Intravenous • US • Approved
  • Oncovin Solution 1mg/ml
    Liquid • 1 mg / mL • Intravenous • Canada • Approved
  • Vincasar PFS
    Injection, solution • 1 mg/1mL • Intravenous • US • Generic • Approved
  • Vincasar PFS
    Injection, solution • 1 mg/1mL • Intravenous • US • Generic • Approved
  • VinCRIStine Sulfate
    Injection, solution • 1 mg/1mL • Intravenous • US • Generic • Approved
  • Vincristine Sulfate Inj 1mg/ml USP
    Liquid • 1 mg / mL • Intravenous • Canada • Approved
  • Vincristine Sulfate Inj 5mg/vial USP
    Powder, for solution • 5 mg / vial • Intravenous • Canada • Approved
Menampilkan 8 dari 12 produk.
International Brands
  • Alcavixin — Korea United Pharma
  • Alcrist — Alkem
  • Citomid — CSC
  • Cytocristin — Cipla
  • Oncocristin — Sun
  • Oncovin — Lilly
  • Oncrivin — Teva
  • Sindovin — Actavis
  • Tevacristin — Teva
  • Vinces — Ivax

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul